The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment

The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment

This article is a review of epidemiology, pathogenesis and treatment of venous thromboembolism (VTE) in cancer patients. In accordance with actual guidelines, the duration of anticoagulant therapy of cancer-related venous thrombosis should be at least 6 months. The use of vitamin K antagonists (VKA)...

Full description

Bibliographic Details
Main Authors: К. V. Lobastov, I. V. Schastlivtsev
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2020-05-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
venous thrombosis
pulmonary embolism
venous thromboembolism
malignancy
direct oral anticoagulants
Online Access:https://www.rpcardio.com/jour/article/view/2177

Internet

https://www.rpcardio.com/jour/article/view/2177

Similar Items